Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAF V600E -induced growth arrest in melanocytes

  • McGrail, Kimberley|||0000-0001-7227-7306
  • Granado-Martínez, Paula|||0000-0002-7765-8914
  • Orsenigo, Roberto
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Nieto, Paula
  • Heyn, Holger|||0000-0002-3276-1889
  • Ferrer, Berta|||0000-0002-1255-4647
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Muñoz Couselo, Eva|||0000-0001-7556-7608
  • García-Patos Briones, Vicente|||0000-0003-1654-6035
  • Recio Conde, Juan Ángel|||0000-0002-7320-3832
The mechanisms behind UVB-initiated, neonatal-specific melanoma linked to BRAF V600E are not well understood, particularly regarding its role in growth arrest. We found that, beyond mutations, neonatal UV irradiation or Lkb1 loss promotes a cell-autonomous transcriptional reprogramming that prevents BRAF V600E -induced growth arrest, leading to melanoma development. Using UVB-dependent and independent mouse models, genomic analyses, clinical data, and single-cell transcriptomics, we identified a transcriptional program that bypasses growth arrest, promoting melanoma. In humans, many of these genes are linked to poor survival and are upregulated in melanoma progression and other RAS pathway-driven tumors. Reconstitution experiments showed these genes cooperate with BRAF V600E in melanocyte transformation, dedifferentiation, and drug resistance. Depleting gene products like UPP1 highlights their potential as therapeutic targets. Our findings reveal that BRAF V600E -mutated melanomas can develop independently of nevus progression and identify novel targets for treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy

  • McGrail Fernández, Kimberley Anne
  • Granado Martinez, Paula
  • Esteve Puig, Rosaura
  • Garcia Ortega, Sara
  • Ding, Yuxin
  • Sanchez-Redondo Campos, Sara
  • Ferrer Fábrega, Berta
  • Hernandez Losa, Javier
  • Canals Suris, Francesc
  • Pérez, Mileidys
  • García-Patos Briones, Vicente
  • Recio Conde, Juan Angel
  • Muñoz Couselo, Eva
Glycolysis; Melanomas; Targeted therapy, Glucólisis; Melanomas; Terapia dirigida, Glucòlisi; Melanomes; Teràpia dirigida, NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however, NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Here, we show that NRASQ61-mutated melanomas specific metabolic settings mediate cell sensitivity to sorafenib upon metabolic stress. Mechanistically, these cells are dependent on glucose metabolism, in which glucose deprivation promotes a switch from CRAF to BRAF signaling. This scenario contributes to cell survival and sustains glucose metabolism through BRAF-mediated phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2/3 (PFKFB2/PFKFB3). In turn, this favors the allosteric activation of phosphofructokinase-1 (PFK1), generating a feedback loop that couples glycolytic flux and the RAS signaling pathway. An in vivo treatment of NRASQ61 mutant melanomas, including patient-derived xenografts, with 2-deoxy-D-glucose (2-DG) and sorafenib effectively inhibits tumor growth. Thus, we provide evidence for NRAS-oncogene contributions to metabolic rewiring and a proof-of-principle for the treatment of NRASQ61-mutated melanoma combining metabolic stress (glycolysis inhibitors) and previously approved drugs, such as sorafenib., This work was funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”) PI14/0375-Fondos FEDER J.A.R., PI17/00043-Fondos FEDER; J.A.R., PI20/0384-Fondos FEDER; J.A.R., Euronanomed2-ISCIII (AC16/00019)-Fondos FEDER; J.A.R., Asociación Española Contra el Cancer (AECC-GCB15152978SOEN) (supported P.G.M., K.M.); J.A.R., Ramón Areces Foundation (supported K.M. and research); J.A.R. (PI17/00412)-Fondos FEDER; R.B., A.M., A.N.S. We thank A. Zorzano’s laboratory for technical assistance and performance of Seahorse technology.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation

  • Granado Martinez, Paula
  • García Ortega, Sara
  • González Sánchez, Elena
  • McGrail Fernández, Kimberley Anne
  • Selgas Sanchis, Rafael
  • Grueso Gragera, Judit
  • Gil Villaverde, Rosa
  • Naldaiz-Gastesi, Neia
  • Rhodes, Ana C
  • Hernandez Losa, Javier
  • Ferrer Fábrega, Berta
  • Canals Suris, Francesc
  • Villanueva Cardús, Josep
  • Mendez Fernández, Olga
  • García-Patos Briones, Vicente
  • Recio Conde, Juan Angel
  • Muñoz Couselo, Eva
Genètica del càncer; Càncer de pulmó; Oncògens, Genética del cáncer; Cáncer de pulmón; Oncogenes, Cancer genetics; Lung cancer; Oncogenes, Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. Here, we investigated the contribution of four missense LKB1 somatic mutations in tumor biology. Three out of the four mutants lost their tumor suppressor capabilities and showed deficient kinase activity. The remaining mutant retained the enzymatic activity of wild type LKB1, but induced increased cell motility. Mechanistically, LKB1 mutants resulted in differential gene expression of genes encoding vesicle trafficking regulating molecules, adhesion molecules and cytokines. The differentially regulated genes correlated with protein networks identified through comparative secretome analysis. Notably, three mutant isoforms promoted tumor growth, and one induced inflammation-like features together with dysregulated levels of cytokines. These findings uncover oncogenic roles of LKB1 somatic mutations, and will aid in further understanding their contributions to cancer development and progression., This work was supported by funds from the Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) PI1400375-Fondos FEDER, PI17/00043-Fondos FEDER, Euronanomed2-ISCIII (AC16/00019)-Fondos FEDER, Asociación Española Contra el Cancer (AECC-GCB15152978SOEN) supported PGM, KM., Ramón Areces Foundation supported KM and research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation

  • Granado-Martínez, Paula|||0000-0002-7765-8914
  • Garcia-Ortega, Sara|||0000-0002-4404-5441
  • González-Sánchez, Elena
  • McGrail, Kimberley|||0000-0001-7227-7306
  • Selgas, Rafael|||0000-0002-5060-3841
  • Grueso, Judit|||0000-0003-1093-7940
  • Gil Villaverde, Rosa
  • Naldaiz-Gastesi, Neia
  • Rhodes, Ana C.
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Ferrer, Berta|||0000-0002-1255-4647
  • Canals, Francesc|||0000-0002-0650-1135
  • Villanueva, Josep|||0000-0003-1396-9470
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz Couselo, Eva|||0000-0001-7556-7608
  • García-Patos Briones, Vicente|||0000-0003-1654-6035
  • Recio Conde, Juan Ángel|||0000-0002-7320-3832
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. Here, we investigated the contribution of four missense LKB1 somatic mutations in tumor biology. Three out of the four mutants lost their tumor suppressor capabilities and showed deficient kinase activity. The remaining mutant retained the enzymatic activity of wild type LKB1, but induced increased cell motility. Mechanistically, LKB1 mutants resulted in differential gene expression of genes encoding vesicle trafficking regulating molecules, adhesion molecules and cytokines. The differentially regulated genes correlated with protein networks identified through comparative secretome analysis. Notably, three mutant isoforms promoted tumor growth, and one induced inflammation-like features together with dysregulated levels of cytokines. These findings uncover oncogenic roles of LKB1 somatic mutations, and will aid in further understanding their contributions to cancer development and progression. Paula Granado-Martínez, Sara Ortega, Elena González-Sánchez et al. report a functional analysis of four cancer-associated mutant isoforms of the gene STK11 using cell-based and animal models. They find the mutant isoforms no longer show tumor suppressor activity, promote tumor growth, and affect the regulation of cytokines and genes involved in vesicle trafficking.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy

  • McGrail Fernández, Kimberley Anne
  • Granado Martinez, Paula
  • Esteve Puig, Rosaura
  • Garcia Ortega, Sara
  • Ding, Yuxin
  • Sanchez-Redondo Campos, Sara
  • Ferrer Fábrega, Berta
  • Hernandez Losa, Javier
  • Canals Suris, Francesc
  • Pérez, Mileidys
  • García-Patos Briones, Vicente
  • Recio Conde, Juan Angel
  • Muñoz Couselo, Eva
Glycolysis; Melanomas; Targeted therapy, Glucólisis; Melanomas; Terapia dirigida, Glucòlisi; Melanomes; Teràpia dirigida, NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however, NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Here, we show that NRASQ61-mutated melanomas specific metabolic settings mediate cell sensitivity to sorafenib upon metabolic stress. Mechanistically, these cells are dependent on glucose metabolism, in which glucose deprivation promotes a switch from CRAF to BRAF signaling. This scenario contributes to cell survival and sustains glucose metabolism through BRAF-mediated phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2/3 (PFKFB2/PFKFB3). In turn, this favors the allosteric activation of phosphofructokinase-1 (PFK1), generating a feedback loop that couples glycolytic flux and the RAS signaling pathway. An in vivo treatment of NRASQ61 mutant melanomas, including patient-derived xenografts, with 2-deoxy-D-glucose (2-DG) and sorafenib effectively inhibits tumor growth. Thus, we provide evidence for NRAS-oncogene contributions to metabolic rewiring and a proof-of-principle for the treatment of NRASQ61-mutated melanoma combining metabolic stress (glycolysis inhibitors) and previously approved drugs, such as sorafenib., This work was funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”) PI14/0375-Fondos FEDER J.A.R., PI17/00043-Fondos FEDER; J.A.R., PI20/0384-Fondos FEDER; J.A.R., Euronanomed2-ISCIII (AC16/00019)-Fondos FEDER; J.A.R., Asociación Española Contra el Cancer (AECC-GCB15152978SOEN) (supported P.G.M., K.M.); J.A.R., Ramón Areces Foundation (supported K.M. and research); J.A.R. (PI17/00412)-Fondos FEDER; R.B., A.M., A.N.S. We thank A. Zorzano’s laboratory for technical assistance and performance of Seahorse technology.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation

  • Granado Martinez, Paula
  • García Ortega, Sara
  • González Sánchez, Elena
  • McGrail Fernández, Kimberley Anne
  • Selgas Sanchis, Rafael
  • Grueso Gragera, Judit
  • Gil Villaverde, Rosa
  • Naldaiz-Gastesi, Neia
  • Rhodes, Ana C
  • Hernandez Losa, Javier
  • Ferrer Fábrega, Berta
  • Canals Suris, Francesc
  • Villanueva Cardús, Josep
  • Mendez Fernández, Olga
  • García-Patos Briones, Vicente
  • Recio Conde, Juan Angel
  • Muñoz Couselo, Eva
Genètica del càncer; Càncer de pulmó; Oncògens, Genética del cáncer; Cáncer de pulmón; Oncogenes, Cancer genetics; Lung cancer; Oncogenes, Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. Here, we investigated the contribution of four missense LKB1 somatic mutations in tumor biology. Three out of the four mutants lost their tumor suppressor capabilities and showed deficient kinase activity. The remaining mutant retained the enzymatic activity of wild type LKB1, but induced increased cell motility. Mechanistically, LKB1 mutants resulted in differential gene expression of genes encoding vesicle trafficking regulating molecules, adhesion molecules and cytokines. The differentially regulated genes correlated with protein networks identified through comparative secretome analysis. Notably, three mutant isoforms promoted tumor growth, and one induced inflammation-like features together with dysregulated levels of cytokines. These findings uncover oncogenic roles of LKB1 somatic mutations, and will aid in further understanding their contributions to cancer development and progression., This work was supported by funds from the Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) PI1400375-Fondos FEDER, PI17/00043-Fondos FEDER, Euronanomed2-ISCIII (AC16/00019)-Fondos FEDER, Asociación Española Contra el Cancer (AECC-GCB15152978SOEN) supported PGM, KM., Ramón Areces Foundation supported KM and research.